Adjuvant endocrine therapy for premenopausal women with early breast cancer

被引：0
作者：
Ting Bao
Nancy E Davidson
机构：
[1] Johns Hopkins University,Sidney Kimmel Comprehensive Cancer Center
来源：
Breast Cancer Research | / 9卷
关键词：
Tamoxifen; Endocrine Therapy; Premenopausal Woman; GnRH Agonist; Exemestane;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.
引用
收藏
相关论文
共 43 条
  • [1] Clarke MJ(1998)Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review BMJ 317 1246-1248
  • [2] Goldhirsch A(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717
  • [3] Wood W(2007)Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer Ann Oncol 18 1133-1144
  • [4] Gelber R(2003)The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women Eur J Cancer 39 861-869
  • [5] Coates AS(2005)Adjuvant endocrine therapy for premenopausal women with early breast cancer J Clin Oncol 23 1736-1750
  • [6] Thürlimann B(2007)Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials Lancet 369 1711-1723
  • [7] Senn H-J(2002)Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 1616-1622
  • [8] Robertson JF(2005)Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312-9318
  • [9] Blamey RW(2007)Role of CYP2D6 testing in selection of endocrine therapy for breast cancer Pharmacogenomics 8 1-3
  • [10] Dellapasqua S(undefined)undefined undefined undefined undefined-undefined
12345